Integrated Filing — IndAS



General information about company
Scrip Code 524816
NSE Symbol NATCOPHARM
MSEI Symbol NOTLISTED
ISIN INE987B01026
Name of company NATCO PHARMA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 12-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 04-Aug-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 12-Aug-2025   11:45:00
End date and time of board meeting 12-Aug-2025   13:05:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 13289000000
Other income 617000000
Total income 13906000000
2 Expenses
(a) Cost of materials consumed 1806000000
(b) Purchases of stock-in-trade 373000000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 151000000
(d) Employee benefit expense 1690000000
(e) Finance costs 32000000
(f) Depreciation, depletion and amortisation expense 576000000
(f) Other Expenses
1 Other Expenses 3559000000 3559000000
Total other expenses 3559000000
Total expenses 8187000000
3 Total profit before exceptional items and tax 5719000000
4 Exceptional items 0
5 Total profit before tax 5719000000
6 Tax expense
7 Current tax 1157000000
8 Deferred tax -241000000
9 Total tax expenses 916000000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 4803000000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period 4803000000
17 Other comprehensive income net of taxes 393000000
18 Total Comprehensive Income for the period 5196000000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 4807000000
Total profit or loss, attributable to non-controlling interests -4000000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 5200000000
Total comprehensive income for the period attributable to owners of parent non-controlling interests -4000000
21 Details of equity share capital
Paid-up equity share capital 358000000
Face value of equity share capital 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 26.84
Diluted earnings (loss) per share from continuing operations 26.84
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 26.84
Diluted earnings (loss) per share from continuing and discontinued operations 26.84
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Pharmaceuticals 12942000000 12942000000
2 Agro chemicals 347000000 347000000
Total Segment Revenue 13289000000
Less: Inter segment revenue
Revenue from operations 13289000000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Pharmaceuticals 5783000000 5783000000
2 Agro chemicals -32000000 -32000000
Total Profit before tax 5751000000
i. Finance cost 32000000 32000000
ii. Other Unallocable Expenditure net off Unallocable income 0 0
Profit before tax 5719000000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Pharmaceuticals 54626000000 54626000000
2 Agro chemicals 2678000000 2678000000
Total Segment Asset 57304000000 57304000000
Un-allocable Assets 34687000000 34687000000
Net Segment Asset 91991000000 91991000000
4 Segment Liabilities
Segment Liabilities
1 Pharmaceuticals 7401000000 7401000000
2 Agro chemicals 440000000 440000000
Total Segment Liabilities 7841000000 7841000000
Un-allocable Liabilities 2833000000 2833000000
Net Segment Liabilities 10674000000 10674000000
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Fair value changes of equity investments through OCI 53000000 53000000
2 Tax impact in fair value changes on equity investments through OCI -7000000 -7000000
Total Amount of items that will not be reclassified to profit and loss 46000000
2 Income tax relating to items that will not be reclassified to profit or loss 0
3 Amount of items that will be reclassified to profit and loss
1 Exchange differences on translating financial statements of foreign operations 347000000 347000000
Total Amount of items that will be reclassified to profit and loss 347000000
4 Income tax relating to items that will be reclassified to profit or loss 0
5 Total Other comprehensive income 393000000